A harm-reduction look at CagriSema, an investigational amylin-plus-GLP-1 combination not yet approved, and what would be worth tracking.
At a glance
Best for
CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist, developed by Novo Nordisk as a once-weekly injection. The two mechanisms stack: GLP-1 blunts appetite and slows gastric emptying, while amylin adds its own satiety signaling. In the REDEFINE program, CagriSema produced roughly 22.7 percent mean weight loss at 68 weeks, versus about 16.0 percent for semaglutide alone and 1.8 percent for placebo.
Importantly, CagriSema is not approved. Novo Nordisk filed an FDA application in December 2025, with a decision expected around late 2026. This is an educational tracking guide about an investigational combination, not medical advice or a recommendation.
In the trials, CagriSema is titrated upward over weeks toward the combined maintenance dose to limit gastrointestinal side effects, and given as a once-weekly subcutaneous injection. Any dose numbers here reflect the trial program only, not a personal recommendation.
The strong trial numbers reflect controlled conditions with titration and support. Weight loss is gradual, and a meaningful share during rapid loss can be lean mass, so protein intake and resistance training deserve dedicated tracking alongside the scale and waist.
CagriSema is investigational and not FDA approved as of mid-2026. Based on its components, expect the GLP-1 class boxed warning for thyroid C-cell tumors and contraindications in medullary thyroid carcinoma or MEN 2, plus nausea, vomiting, diarrhea, and risks of pancreatitis, gallbladder disease, and dehydration. Anyone accessing it outside a trial is outside the evidence base and should be under medical supervision.
Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.